SEARCH

SEARCH BY CITATION

References

  • Bakema JE, Ganzevles SH, Fluitsma DM, Schilham MW, Beelen RH, Valerius T, Lohse S, Glennie MJ, Medema JP, van EM (2011) Targeting FcalphaRI on polymorphonuclear cells induces tumor cell killing through autophagy. J Immunol 187: 726-732
  • Bakema JE, van Egmond M (2011) The human immunoglobulin A Fc receptor FcalphaRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol 4: 612-624
  • Beyer T, Lohse S, Berger S, Peipp M, Valerius T, Dechant M (2009) Serum-free production and purification of chimeric IgA antibodies. J Immunol Methods 346: 26-37
  • Bibeau F, Lopez-Crapez E, Di FF, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frebourg T, Michel P, Sabourin JC, Boissiere-Michot F (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27: 1122-1129
  • Biburger M, Aschermann S, Schwab I, Lux A, Albert H, Danzer H, Woigk M, Dudziak D, Nimmerjahn F (2011) Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35: 932-944
  • Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, van Dijk MA, et al (2004) Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 173: 4699-4707
  • Bogers WM, Gorter A, Stuurman ME, Van Es LA, Daha MR, (1989) Clearance kinetics and tissue distribution of aggregated human serum IgA in rats. Immunology 67: 274-280
  • Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, et al (2011) The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 96: 1822-1830
  • Bracke M, Nijhuis E, Lammers JW, Coffer PJ, Koenderman L (2000) A critical role for PI 3-kinase in cytokine-induced Fcalpha-receptor activation. Blood 95: 2037-2043
  • Chao MP, Weissman IL, Majeti R (2012) The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24: 225-232
  • Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443-446
  • Cordier G, Samarut C, Revillard JP (1981) Distinct functions of surface receptors in the induction of neutrophil-mediated cytotoxicity. Ann Immunol (Paris) 132D: 3-14
  • de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, et al (2010) In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 70: 3209-3217
  • Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, van de Winkel JG, Valerius T (2007) Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 179: 2936-2943
  • Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, van de Winkel JG, Valerius T (2002) Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 100: 4574-4580
  • Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, et al (2008) Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 68: 4998-5003
  • Elsasser D, Stadick H, Stark S, van de Winkel JG, Gramatzki M, Schrott KM, Valerius T, Schafhauser W (1999) Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma. Anticancer Res 19: 1525-1528
  • Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF (2006) Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 203: 743-753
  • Junghans RP, Anderson CL (1996) The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93: 5512-5516
  • Kim R (2009) Cetuximab and panitumumab: are they interchangeable? Lancet Oncol 10: 1140-1141
  • Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7: 301-311
  • Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, van der Winkel JG, Leusen JH, et al (2012) Characterisation of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J Biol Chem 287: 25139-25150
  • Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, van de Winkel JG, Dechant M, Valerius T (2011) Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol 186: 3770-3778
  • Lohse S, Peipp M, Beyer T, Valerius T, Dechant M (2010) Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies. Arch Immunol Ther Exp (Warsz) 58: 303-312
  • Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, Haas KM, Tedder TF (2008) Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 112: 1205-1213
  • Monteiro RC, van de Winkel JG (2003) IgA Fc receptors. Annu Rev Immunol 21: 177-204
  • Otten MA, Leusen JH, Rudolph E, van der Linden JA, Beelen RH, van de Winkel JG, van Egmond M (2007) FcR gamma-chain dependent signaling in immature neutrophils is mediated by FcalphaRI, but not by FcgammaRI. J Immunol 179: 2918-2924
  • Overdijk MB, Verploegen S, Ortiz BA, Vink T, Leusen JH, Bleeker WK, Parren PW (2012) Crosstalk between human IgG isotypes and murine effector cells. J Immunol 189: 3430-3438
  • Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, Parren PW, Bleeker WK (2011) Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 187: 3383-3390
  • Peipp M, Dechant M, Valerius T (2008a) Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 20: 436-443
  • Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, Repp R, van Berkel PH, Vink T, van de Winkel JG, et al (2008b) Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112: 2390-2399
  • Peipp M, Schneider-Merck T, Dechant M, Beyer T, van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, Valerius T (2008c) Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. J Immunol 180: 4338-4345
  • Rifai A, Fadden K, Morrison SL, Chintalacharuvu KR (2000) The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. J Exp Med 191: 2171-2182
  • Rifai A, Mannik M (1983) Clearance kinetics and fate of mouse IgA immune complexes prepared with monomeric or dimeric IgA. J Immunol 130: 1826-1832
  • Royle L, Campbell MP, Radcliffe CM, White DM, Harvey DJ, Abrahams JL, Kim YG, Henry GW, Shadick NA, Weinblatt ME, et al (2008) HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem 376: 1-12
  • Royle L, Roos A, Harvey DJ, Wormald MR, van Gijlswijk-Janssen D, Redwan el-RM, Wilson IA, Daha MR, Dwek RA, Rudd PM (2003) Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem 278: 20140-20153
  • Sancho J, Gonzalez E, Rivera F, Escanero JF, Egido J (1984) Hepatic and kidney uptake of soluble monomeric and polymeric IgA aggregates. Immunology 52: 161-167
  • Sell S, Fahey JL (1964) Relationship between gamma-globulin metabolism and low serum gamma-globulin in germ-free mice. J Immunol 93: 81-87
  • Stockert RJ, Kressner MS, Collins JC, Sternlieb I, Morell AG (1982) IgA interaction with the asialoglycoprotein receptor. Proc Natl Acad Sci USA 79: 6229-6231
  • Stockmeyer B, Dechant M, van EM, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, et al (2000) Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol 165: 5954-5961
  • Sunada H, Magun BE, Mendelsohn J, MacLeod CL (1986) Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83: 3825-3829
  • Tarelli E, Smith AC, Hendry BM, Challacombe SJ, Pouria S (2004) Human serum IgA1 is substituted with up to six O-glycans as shown by matrix assisted laser desorption ionisation time-of-flight mass spectrometry. Carbohydr Res 339: 2329-2335
  • Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, Van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, et al (1997) FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 90: 4485-4492
  • van Egmond M, van Garderen E, van Spriel AB, Damen CA, van Amersfoort ES, van Zandbergen G, van Hattum J, Kuiper J, van de Winkel JG (2000) FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med 6: 680-685
  • van Egmond M, van Vuuren AJ, Morton HC, van Spriel AB, Shen L, Hofhuis FM, Saito T, Mayadas TN, Verbeek JS, van de Winkel JG (1999) Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). Blood 93: 4387-4394
  • van Spriel AB, van Ojik HH, Bakker A, Jansen MJ, van de Winkel JG (2003) Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 101: 253-258
  • Woof JM, Kerr MA (2006) The function of immunoglobulin A in immunity. J Pathol 208: 270-282